BPC-157 Protocol in Cape Town: A Practical, GP-Led Guide

BPC-157 — body protection compound, a 15-amino-acid fragment originally isolated from human gastric juice — is the peptide that brought most South African biohackers into the field. The animal data on healing is striking; the human data is sparse but growing.¹ If you're going to run a BPC-157 protocol in Cape Town, this is the framework we use.

Legal status in South Africa

BPC-157 is not registered with SAHPRA as a medicine. It is legally accessible through compounding pharmacies on prescription from a registered medical practitioner, and through clearly-labelled research-use channels. We strongly recommend the prescription route — it gives you traceability, a clinician who can intervene if something goes sideways, and certificates of analysis that match the vial.

Typical research dosing

The published clinical literature is thin; most dosing in human use is extrapolated from rodent studies and clinical experience reports.² Common ranges seen in protocols:

• Systemic (subcutaneous): 250–500 mcg once or twice daily
• Localised injury: 250 mcg injected near (not into) the injured tendon or joint, once daily
• Oral (gut-focused): 500 mcg once daily, taken in the morning
• Cycle length: 4–6 weeks on, 2–4 weeks off

What to track

BPC-157 protocols live or die on objective measurement. We use:

• Baseline pain/function score for the target tissue (VAS 0–10, daily)
• Range-of-motion or strength benchmark at week 0, 2, 4, 6
• CRP and full blood count at baseline and end of cycle
• Lipid panel — there's a theoretical concern about vasoactive effects worth monitoring³
• Subjective sleep & GI score 1–10 daily

Sourcing locally

Cape Town's compounding pharmacy network has matured fast over the last three years. The standards to insist on are non-negotiable:

• Third-party HPLC + mass-spec COA matched to the vial lot number
• ≥99% purity threshold
• Cold-chain shipping for lyophilised vials
• Bacteriostatic water supplied separately, with documented provenance

If a supplier can't produce a COA on request, walk away. The peptide industry's biggest quality problem is mislabelled or underdosed product, and a COA is your only line of defence.⁴

GP oversight

Find a doctor who will work with you. The Peptide South Africa medical network includes Cape Town GPs experienced with peptide research protocols who'll run baseline bloodwork, check in mid-cycle, and adjust if markers move. This isn't optional in our model — it's the difference between a protocol and an experiment on yourself.

Reasonable expectations

Most people who run BPC-157 for a tendinopathy or post-surgical recovery report meaningful improvement by week 3–4. People running it 'for general health' report less consistent benefit, which matches the mechanistic literature — BPC-157 appears to act primarily where there's tissue damage to repair.⁵